Abstract: The invention provides agents and vaccines for treating and diagnosing celiac disease. In particular, the present invention provides a combination of three peptides that are useful for treating and diagnosing celiac disease in a large proportion of patients.

Abstract: Provided herein are compositions and methods for treating subjects with Celiac disease, e.g., specific dosages and dosage schedules of a composition comprising at least one gluten peptide for use in treating subjects with Celiac disease.

Abstract: Provided herein are methods and compositions for treating subjects with Celiac disease.

Abstract: Provided herein are compositions and methods for treating autoimmune diabetes such as type 1 diabetes (T1D), diagnosing autoimmune diabetes such as T1D, assessing treatment efficacy, and selecting subjects for treatment, e.g., using a peptide or epitope disclosed.

Abstract: Provided herein are methods of adjusting or selecting a gluten peptide therapy based on the human leukocyte antigen (HLA) genotype, in particular HLA-DQ2.5 homozygosity, of a subject having or suspected of having Celiac disease. Also provided herein are methods of identifying (e.g., diagnosing) a subject, such as a subject having or suspected of having Celiac disease and/or assessing the efficacy of treatment of Celiac disease, e.g. by determining responsiveness to a therapeutic gluten peptide composition or cytokine response, and kits relating thereto.

Abstract: Provided herein are compositions and methods for treating autoimmune diabetes such as type 1 diabetes (T1D), diagnosing autoimmune diabetes such as T1D, assessing treatment efficacy, and selecting subjects for treatment, e.g., using a peptide or epitope disclosed.

Abstract: Provided herein are methods and compositions for treating subjects with Celiac disease.

Abstract: Provided herein are methods of adjusting or selecting a gluten peptide therapy based on the human leukocyte antigen (HLA) genotype, in particular HLA-DQ2.5 homozygosity, of a subject having or suspected of having Celiac disease. Also provided herein are methods of identifying (e.g., diagnosing) a subject, such as a subject having or suspected of having Celiac disease and/or assessing the efficacy of treatment of Celiac disease, e.g. by determining responsiveness to a therapeutic gluten peptide composition or cytokine response, and kits relating thereto.

Abstract: Provided herein are specific dosages and dosage schedules of a composition comprising at least one gluten peptide for use in treating subjects with Celiac disease.

Abstract: Provided herein are methods and compositions for evaluating a subject having or suspected of having Celiac disease.

Abstract: The invention provides agents and vaccines for treating and diagnosing celiac disease. In particular, the present invention provides a combination of three peptides that are useful for treating and diagnosing celiac disease in a large proportion of patients.

Abstract: Provided herein are compositions and methods for treating and/or identifying children having or suspected of having Celiac disease.

Abstract: Provided herein are methods of adjusting or selecting a gluten peptide therapy based on the human leukocyte antigen (HLA) genotype, in particular HLA-DQ2.5 homozygosity, of a subject having or suspected of having Celiac disease. Also provided herein are methods of identifying (e.g., diagnosing) a subject, such as a subject having or suspected of having Celiac disease and/or assessing the efficacy of treatment of Celiac disease, e.g. by determining responsiveness to a therapeutic gluten peptide composition or cytokine response, and kits relating thereto.

Abstract: The invention provides agents and vaccines for treating and diagnosing celiac disease. In particular, the present invention provides a combination of three peptides that are useful for treating and diagnosing celiac disease in a large proportion of patients.

Abstract: Provided herein are methods of identifying a subject having or at risk for having Celiac disease by determining a level of IL-2 in a sample from a subject.

Abstract: Provided herein are compositions, kits, and methods for measuring circulating cytokines and chemokines in a subject that has or is suspected of having Celiac disease.

Abstract: Provided herein are methods of identifying a subject having or at risk for having Celiac disease by determining a level of IP-10 in a sample from a subject.

Abstract: Provided herein are compositions, methods, and kits related to compositions comprising at least one gluten peptide. In some aspects, compositions, methods, and kits useful for subjects having Celiac disease.

Abstract: Provided herein are methods and kits for assaying antigen-specific T cell responses, such as rare autoantigen-specific T cell responses, by measuring a level of IP-10 in a sample from a subject having or suspected of having an autoimmune disease, an allergy, an infectious disease or condition, or an adverse immune condition caused by administration of an isolated, recombinant or synthetic protein or peptide. Also provided herein are methods and kits for assaying a T cell response to an antigen peptide, such as an islet autoantigen peptide, such as measuring a T cell response to at least one antigen peptide, such as an islet autoantigen peptide, in a sample from a subject, such as one having or suspected of having Type 1 Diabetes (TID), Celiac disease or both.

Abstract: A method and apparatus to securely distribute embedded firmware to a module in an industrial control system is disclosed. A security certificate corresponding to the firmware is generated utilizing a proprietary algorithm. The certificate includes an identifier corresponding to the module on which the firmware is to be loaded and an identifier corresponding to a removable medium on which the firmware is distributed. The removable medium is inserted into the module in the industrial control system on which the firmware is to be loaded. The module reads the security certificate and verifies that the firmware is intended for the module and verifies that the security certificate includes the identifier for the removable medium which was inserted into the module. If the firmware is intended for the module and the security certificate includes the identifier for the removable medium, the module loads the firmware from the removable medium.